VEGFA and hepatocellular carcinoma: Sub-group analysis according to treatment line showed that the use of anti-VEGF agents significantly improved PFS in elderly HCC patients who relapsed after a first-line sorafenib treatment (HR 0.55, 95% CI: 0.45–0.67, p < 0.001, Figure 2), while the use of anti-VEGF agents as first-line treatment did not significantly improved PFS in this patients population (HR 0.87, 95% CI: 0.67–1.13, p = 0.29).